ABSTRACT Background. The androgen receptor (AR) is a commonlyexpressed hormone receptor in breast cancer and may be a marker of response to targeted anti-androgen therapy, a particularly attractive option for triple-negative breast cancer (TNBC). Gene expression studies suggest that ARs may distinguish a luminal/AR TNBC subtype from stem cell-like subtypes. TNBC frequency is two to three times higher in African American and African breast cancers compared with White American and European breast cancers, yet little is known regarding TNBC subtypes in high-frequency African-ancestry populations. We evaluated ARs and the mammary stem cell marker aldehyde dehydrogenase 1 (ALDH1) among breast cancers from Ghana, Africa. Methods. Overall, 147 formalin-fixed, paraffin-embedded invasive breast cancers from the Komfo Anoyke Teaching Hospital in Ghana were studied at the University of Michigan, and analyzed immunohistochemically for estrogen receptor (ER), progesterone receptor (PR), HER2/ neu, ALDH1, and AR expression. Results. The median age of patients was 45 years. Only 31 cases (21 %) were ER-positive, and 14 (10 %) were HER2-positive; 89 (61 %) were TNBCs. For the entire group, 44 % were AR-positive and 45 % were ALDH1-positive. ER/PR-positive tumors were more likely to be AR-positive compared with ER/PR-negative tumors (87 vs. 26 %; p \ 0.0001), but there was no association between ALDH1 and AR expression. Among the TNBC cases, 45 % were ALDH1-positive and 24 % were AR-positive. ALDH1 positivity was associated with AR positivity within the subset of TNBC (36 vs. 14 %; p = 0.019). Conclusion. We confirmed other studies showing a high frequency of TNBC in Africa. Surprisingly, ALDH1 was found to correlate with AR expression among TNBC, suggesting that novel TNBC subtypes may exist among populations with African ancestry.
with basal breast cancer as those whose cancers are negative for expression of the estrogen receptor (ER), the progesterone receptor (PR), and the HER2/neu marker; this phenotype is commonly known as triple-negative breast cancer (TNBC). While the majority (approximately 80 %) of TNBC tumors are indeed of the basal subtype, there is substantial diversity in the biologic behavior of these tumors. 3, 4 Some of this variation in TNBC tumor biology can be appreciated in relation to histologic patterns, and recent gene expression studies of TNBC cases have identified at least six different TNBC subtypes with varying degrees of luminal versus mesenchymal/stem cell-like features. 5, 6 Distinguishing the TNBC subtypes is likely to be clinically relevant as the luminal subtype is less likely to respond to neoadjuvant chemotherapy 7 but may be amenable to novel endocrine therapies, such as anti-androgen manipulation. [8] [9] [10] [11] [12] [13] Generating a complete profile of TNBC subtypes is therefore important; however, the studies reported to date have been based on data from European, American (predominately Caucasian), and Asian populations. TNBC is more prevalent among African American and sub-Saharan African breast cancer patients, yet little is known about TNBC subtypes in these populations. We used immunohistochemistry (IHC) evaluations of androgen receptors (ARs) and the mammary stem cell marker aldehyde dehydrogenase 1 (ALDH1) to generate novel information regarding the luminal versus stem cell-like characteristics of TNBC cases from the sub-Saharan African country of Ghana.
METHODS
The conduct of this research was approved by the University of Michigan (UM) Institutional Review Board and the Committee on Human Research Publication and Ethics, Kwame Nkrumah University of Science and Technology College of Health Sciences, School of Medical Sciences, Komfo Anoyke Teaching Hospital, Kumasi, Ghana.
The presence of invasive carcinoma in all specimens was first confirmed at the University of Michigan by histopathologic evaluation of the hematoxylin and eosin-stained slides. IHC was then performed at the University of Michigan for expression of ER, PR, HER2/neu (HER2), and ALDH1.
Briefly, paraffin-embedded tissue blocks were sectioned at 5 lm and placed on charged slides. Slides were deparaffinized in xylene and rehydrated through graded alcohols to buffer. Peroxidase blocking was performed. No slide pretreatments were used for cerB-2 (Her 2/neu) because of the heightened fragility and limited supply of these unique specimens that were preserved in the pathology laboratories of a substantially underresourced country. Pretreatment in citrate buffer pH 6.0 was used for ERs, PRs, and ARs. EDTA was used for ALDH1. 
RESULTS
Invasive breast cancer samples from 147 Ghanaian women were available for analyses. Thirteen cases (8.8 %) had inadequate tissue for evaluation of AR expression; the remaining 134 cases (91.2 %) had adequate tissue available for immunohistochemical evaluation of all five markers (ER, PR, HER2/neu, AR, and ALDH1). Clinicopathologic characteristics for the study patient population are shown in Table 1 . Due to the sparse medical record-keeping and tumor registry resources at the Komfo Anoyke Teaching Hospital, very limited clinical information was available for the cases analyzed. The median patient age was 45 years (range 28-76). Three-quarters of all cases were ER-negative (116/147, 78.9 %) and 60.5 % (89/147) were triple negative. For the entire group (n = 147), 66 (45 %) were ALDH1-positive, and for those with AR status (n = 134), 59 (44 %) were AR-positive. Hormone receptor-positive tumors were more likely to be AR-positive compared with ER/PR-negative tumors (87 vs. 26 %; p \ 0.0001), but there was no association between ALDH1 and AR expression (Tables 2, 3 ). Among the TNBC cases, 45 % were ALDH1-positive and 24 % were AR-positive. As shown in Table 4 , ALDH1 positivity was associated with AR positivity within the subset of TNBC tumors (36 vs. 14 %; p = 0.019).
DISCUSSION
The biologic heterogeneity of breast cancer is clearly documented by data from genetic profiling studies.
1,2 The four general categories (subtypes) of invasive tumors that have been most extensively studied are luminal A, luminal B, HER2-positive, and basal. These subtypes vary prognostically as well as with regard to treatment sensitivity and targeted therapies. The luminal subtypes tend to be the most biologically favorable tumors because they can be manipulated with endocrine therapies; the HER2/neuoverexpressing tumors can be managed with the expanding array of commercially available anti-HER/neu agents. In contrast, the basal subtype tends to be a biologically more aggressive pattern of disease, and in clinical practice we identify these as the TNBCs.
TNBC is defined as an invasive breast tumor that is negative by IHC for both the ER and the PR, and negative for evidence of HER2/neu overexpression by IHC and/or FISH analysis. It is important to emphasize that while there is approximately 80 % overlap between TNBC and the basal breast cancer subtype, these two patterns of disease are not synonymous. Substantial diversity in histology and tumor biology exist within the group of cancers that are negative for all three tumor markers, 3, 4 and genetic profiling studies are now defining TNBC subtypes that have varying degrees of chemosensitivity, risk of relapse, and response rates to neoadjuvant chemotherapy. 5, 7, 16 Lehmann et al. evaluated the gene expression profiles from 21 publicly available datasets (including 587 cases of TNBC), and identified six different TNBC subtypes by cluster analyses. 5 These TNBC subtypes featured a spectrum of inherent degrees of aggressiveness and prominence of particular pathways, such as the luminal AR subtype (LAR) and the mesenchymal stem cell-like (MSL), with expression of the mammary stem cell marker ALDH1 17 being prominent in the latter MSL subtype. Furthermore, distinguishing between TNBC subtypes may have significant clinical relevance since the LAR subtype is associated with substantially lower rates of response to neoadjuvant chemotherapy, as shown in a study from the MD Anderson Cancer Center. 7 Expression of the AR by IHC may therefore play a role in the clinical applicability of TNBC subtyping, and AR expression among TNBC cases opens the door to possible targeted anti-AR therapy for these tumors. [9] [10] [11] 16, 18, 19 The mammary stem cell marker ALDH1 also appears to be prominent in differentiating the genetics of TNBC subtypes.
The hypothesis-generating prospect of more refined insights regarding TNBC prognoses and treatments based upon expression of AR is exciting but data regarding the full spectrum of TNBC pathology and genetics are unfortunately limited. In particular, data regarding TNBC subtypes have been predominantly generated by populations with European and East Asian backgrounds. These populations typically have TNBC frequencies of 20 % or lower. In contrast, populations known to have a higher frequency of TNBC, such as those with African ancestry (African Americans and sub-Saharan Africans) have been underrepresented in studies of both TNBC subtypes and AR expression. The landmark Lehmann et al. study included no datasets from Africa. Although no details are available on the racial/ethnic distribution of the six American datasets among the 21 analyzed, it is likely that African Americans contributed a minority of the cases evaluated.
As insights regarding TNBC subtypes advance, it will be essential to ensure that the full spectrum of TNBC cases are studied, including those that represent the diverse 
CONCLUSION
In general, reviews of non-African breast cancer patient populations demonstrate that the AR is expressed in 60-90 % of cases 8, 22 but usually fewer than half of TNBC cases. 9 We found a somewhat lower proportion of AR expression in the complete sample of Ghanaian breast cancers (44 %) but a similarly low frequency of AR expression in TNBC cases (24 %). Our finding that ALDH1 positivity among the TNBC cases was associated with an increased likelihood of AR positivity was somewhat surprising since the existing TNBC subtype studies suggest that androgenic pathways are distinct from the mesenchymal stem cell pathways in these subtypes. However, our study is notably limited in that we looked at very few molecular markers compared with the many pathways evaluated in the gene expression studies of TNBC subtypes. We currently have ongoing studies involving evaluations of additional markers (e.g. cytokeratins and Ki67) on Ghanaian as well as American specimens based on tumor microarrays that we have created. Furthermore, we do not know the extent to which IHC evaluation of tumor markers correlates with the various gene expression and cell cycle pathways. Nonetheless, our findings support the need for further investigation of TNBC subtypes in populations with African ancestry. These future studies may well elucidate other, as-yet uncharacterized, TNBC subtypes and markers for targeted TNBC therapeutics.
